Investor R&D Day 2023
Welcome to Investor R&D Day 2023
September 28, 2023
Agenda and webcast replay
Next Generation Maravai: Extraordinary Science. Everyday Miracles.
Trey Martin, Chief Executive Officer
Customer’s First Choice: Leading Innovation
Kate Broderick, PhD, Chief Innovation Officer
Biologics Safety Testing
Overview and Strategy
Christine Dolan, Chief Operating Officer, Biologics Safety Testing
Innovation
Eric Bishop, VP of Research and Development, Cygnus Technologies
Financial Outlook
Next Generation: Investments and Financial Outlook
Kevin Herde, Chief Financial Officer
Speakers
Deb Hart
Senior Director
Investor Relations
Trey Martin
Chief Executive Officer
Kate Broderick, PhD
Chief Innovation Officer
Drew Burch
EVP, Nucleic Acid Products
Chad Decker
EVP, Enzymes
Becky Buzzeo
Chief Commercial Officer
Christine Dolan
Chief Operating Officer
Biologics Safety Testing
Eric Bishop
Vice President, R&D
Biologics Safety Testing
David Cetlin
Senior Director, R&D
Biologics Safety Testing
Kevin Herde
EVP, Chief Financial Officer
Innovation at Maravai
Supporting documents
Plasmid production services for mRNA manufacturing | Reference Guide
Seamlessly integrate phase-appropriate, high-quality plasmid DNA templates into the mRNA manufacturing process
Bioprocess International, Special Report | Host Cell Protein Analysis
Immunoassays and Orthogonal Characterization by Antibody Affinity Extraction and Mass Spectrometry Methods
Predicting Viral Clearance in Downstream Process Development
Application of a Novel Analytical Approach, David Cetlin
